A GIP-GLP-1 dual agonist compound

By designing GIP-GLP-1 dual agonist compounds, the problems of low biological activity and easy inactivation of existing compounds have been solved, achieving more efficient blood sugar lowering and weight loss effects, and making them suitable for the treatment of a variety of diseases.

CN117229364BActive Publication Date: 2026-11-17CHENGDU AODA BIOTECHNOLOGY CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202210630257.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-06
Publication Date
2026-11-17
Estimated Expiration
2042-06-06

AI Technical Summary

Technical Problem

Existing GIP and GLP-1 compounds have low bioactivity in clinical applications, resulting in the need for high dosages and significant side effects. Furthermore, natural peptides are easily inactivated by DPP IV, making it difficult to achieve long-term metabolic control.

Method used

A GIP-GLP-1 dual agonist compound was designed, which contains a specific amino acid sequence and modification. It can stimulate human glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor, and has high biological activity and stability. It is not easily degraded by DPP-IV.

Benefits of technology

It achieves higher bioactivity and hypoglycemic effect, reduces clinical dosage, reduces side effects, has significant hypoglycemic and weight loss effects, and is suitable for the treatment of a variety of diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

This invention relates to the field of pharmaceutical synthesis and discloses a GIP-GLP-1 dual agonist compound. The GIP-GLP-1 dual agonist compound of this invention is used to prepare pharmaceutical compositions for treating diseases, specifically in the preparation of remedies for at least one of the following diseases: type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, liver fibrosis, and pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a GIP-GLP-1 dual agonist compound and its use, which is a class of dual incretin peptide mimics that stimulate the human glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Background Technology

[0002] GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β-cells in the presence of glucose and protecting pancreatic β-cells. GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic β-cells, and inhibits glucagon secretion, gastric emptying, and food intake, leading to weight loss. GIP and GLP-1 are collectively known as incretins; incretin receptor signaling plays a crucial physiological role in glucose homeostasis. In normal physiology, GIP and GLP-1 are secreted from the intestines after meals. These incretins enhance physiological responses to food, including satiety, insulin secretion, and nutrient processing.

[0003] The most common side effect of GLP-1 compounds is that administration does not achieve full glycemic control and weight loss, while GIP alone has a very modest glucose-lowering capacity in patients with type 2 diabetes. Both natural GIP and GLP-1 can be rapidly inactivated by the ubiquitous protease DPP IV, and therefore can only be used for short-term metabolic control.

[0004] WO 2013 / 164483 and WO 2014 / 192284 reported that certain GIP / GLP-1 compounds exhibited activity of both GIP and GLP-1, and found that these compounds could achieve better glycemic control and weight loss.

[0005] Tirzepatide is a GIP / GLP-1 compound. Due to its relatively low biological activity, the clinical dosage is relatively high. The purpose of this invention is to seek derivatives with higher biological activity to reduce the clinical dosage and corresponding side effects. Summary of the Invention

[0006] This invention provides a GIP-GLP-1 dual agonist compound and its use. The compound is a dual incretin peptide mimic compound that stimulates the human glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

[0007] To achieve the above objectives, the present invention first provides a compound shown in structure I, a pharmaceutically usable salt, solvate, chelate or non-covalent complex of the compound, a drug precursor based on the compound, or any mixture thereof.

[0008]

[0009] In structure I, AA1 is either Gly-Gy or 5-Ava;

[0010] In structure I, AA2 is either NH2 or OH;

[0011] In structure I, m1 is an integer from 1 to 10;

[0012] In structure I, m2 is an integer from 1 to 10;

[0013] In structure I, R stands for HO2C(CH2). n1 CO-(AA3) n2 -(PEG n3 (CH2) n4 CO) n5 -; or HO2C(CH2) n1 CO-(AA3) n2 -(AA4) n6 -:in:

[0014] n1 is an integer between 10 and 20;

[0015] n2 is an integer from 1 to 5;

[0016] n3 is an integer from 1 to 30;

[0017] n4 is an integer from 1 to 5;

[0018] n5 is an integer from 1 to 5;

[0019] n6 is an integer from 1 to 10;

[0020] AA3 may be γGlu, εLys, β-Ala, γ-aminobutyric acid, or 5-Ava;

[0021] AA4 could be Gly, Ser, Asp, Glu, Ada, Apm, or Asu.

[0022] The present invention also provides pharmaceutical compositions comprising compounds according to the present invention, and provides pharmaceutical uses of pharmaceutical compositions comprising compounds according to the present invention for the preparation of a medicine for treating diseases.

[0023] Preferably, the pharmaceutical composition is used in the preparation of a medicament for treating at least one of the following diseases: type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, liver fibrosis, and pulmonary fibrosis.

[0024] Preferably, the pharmaceutical composition is used in the preparation of a medicament for treating delayed efficacy of type 2 diabetes and / or preventing the exacerbation of type 2 diabetes.

[0025] Preferably, the pharmaceutical composition is used in the preparation of a medicament for reducing food intake, reducing β-cell apoptosis, increasing pancreatic β-cell function, increasing β-cell clusters and / or restoring glucose sensitivity to β-cells.

[0026] The present invention further provides a method for administering the compound to a treatment subject to regulate blood glucose levels.

[0027] Further details of this invention are described in detail below, or some of them may be experienced in the embodiments of this invention.

[0028] Unless otherwise specified, the quantities of different components and reaction conditions used herein are to be interpreted as "approximate" or "about". Accordingly, unless otherwise specified, the numerical parameters cited below and in the claims are approximate parameters, and different numerical parameters may be obtained under their respective experimental conditions due to different standard errors.

[0029] In this document, when there is disagreement or ambiguity regarding the chemical structure and name of a compound, the compound is defined precisely by its chemical structure. The compounds described herein may contain one or more chiral centers, and / or double bonds and similar structures, and may also exist as stereoisomers, including isomers of double bonds (e.g., geometric isomers), optical enantiomers, or diastereomers. Accordingly, any chemical structure within the scope of this description, whether partially or entirely containing similar structures, includes all possible enantiomers and diastereomers of the compound, including any single stereoisomer (e.g., a single geometric isomer, a single enantiomer, or a single diastereomer) and any mixture of these isomers. Mixtures of racemic and stereoisomers can be further separated into enantiomers or stereoisomers of their constituent parts by those skilled in the art using continuous separation techniques or chiral molecule synthesis methods.

[0030] Compounds of Formula I include, but are not limited to, optical isomers, racemates, and / or other mixtures of these compounds. In the above cases, a single enantiomer or diastereomer, such as an optically active isomer, can be obtained by asymmetric synthesis or by racemic resolution. Racemic resolution can be achieved by various methods, such as conventional recrystallization with a resolving agent or by chromatographic methods. Additionally, compounds of Formula I also include cis and / or trans isomers with double bonds.

[0031] The compounds described in this invention include, but are not limited to, the compounds shown in structural formula I and all their various pharmaceutically available forms. These pharmaceutically available forms of the compounds include various pharmaceutically acceptable salts, solvates, complexes, chelates, non-covalent complexes, drug prodrugs based on the above-described substances, and any mixtures of these forms.

[0032] The compound shown in Structure I provided by this invention is stable and not easily degraded by dipeptidyl peptidase IV (DPP-IV) in the body. It is a GIP / GLP-I dual agonist compound with significant hypoglycemic and weight-reducing effects. Detailed Implementation

[0033] This invention discloses a GIP / GLP-1 compound and its uses. Those skilled in the art can refer to this document and appropriately modify the relevant parameters to achieve the desired results. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The method of this invention has been described through preferred embodiments. Those skilled in the art can obviously modify or appropriately change and combine the compounds and preparation methods described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.

[0034] The Chinese names corresponding to the English abbreviations used in this invention are shown in the table below:

[0035] English abbreviations Chinese name English abbreviations Chinese name Fmoc 9-fluorenemethyloxycarbonyl OtBu tert-butoxy tBu tert-butyl Boc tert-Butoxycarbonyl group Trt Triphenylmethyl Pbf (2,3-Dihydro-2,2,4,6,7-pentamethylbenzofuran-5-yl)sulfonyl Ala alanine Leu Leucine Arg Arginine Lys Lysine Asn Asparagine Phe Phenylalanine Asp Aspartic acid Pro proline Cys Cysteine Ser Serine Gln glutamine Thr threonine Glu glutamic acid Trp Tryptophan Gly glycine Tyr Tyrosine His Histidine Val Valine Ile Isoleucine Dab 2,4-Diaminobutyric acid 5-Ava 5-Aminovaleric acid Orn ornithine Aib Aminoisobutyric acid Dah 2,7-Diaminoheptanoic acid Dap 2,3-Diaminopropionic acid Dao 2,8-Diaminooctanoic acid Ada 2-Aminohexanoic acid Apm 2-Aminopeptidic acid Asu 2-Aminooctanoic acid

[0036] Example 1: Preparation of the compound

[0037] The preparation method includes: preparing peptide resin using a solid-phase peptide synthesis method, followed by acid hydrolysis of the peptide resin to obtain a crude product, and finally purification of the crude product to obtain a pure product; wherein the solid-phase peptide synthesis method for preparing peptide resin involves sequentially inserting corresponding protected amino acids or fragments from the peptide sequence onto a carrier resin via a solid-phase coupling synthesis method to prepare the peptide resin.

[0038] In the above preparation method, the amount of Fmoc-protected amino acid or protected amino acid fragment is 1.2 to 6 times the total molar amount of the resin added; preferably 2.5 to 3.5 times.

[0039] In the above preparation method, the substitution value of the carrier resin is 0.2 to 1.0 mmol / g resin, and the preferred substitution value is 0.3 to 0.5 mmol / g resin.

[0040] As a preferred embodiment of the present invention, the solid-phase coupling synthesis method is as follows: the protected amino acid-resin obtained in the previous step is deprotected by the Fmoc protecting group and then coupled with the next protected amino acid. The deprotection time for the Fmoc protecting group is 10-60 minutes, preferably 15-25 minutes. The coupling reaction time is 60-300 minutes, preferably 100-140 minutes.

[0041] The coupling reaction requires the addition of a condensing agent, selected from DIC (N,N-diisopropylcarbodiimide), N,N-dicyclohexylcarbodiimide, benzotriazol-1-yl-oxytripyrrolylphosphine hexafluorophosphate, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylurea hexafluorophosphate, benzotriazol-N,N,N',N'-tetramethylurea hexafluorophosphate, or O-benzotriazol-N,N,N',N'-tetramethylurea tetrafluoroborate; preferably N,N-diisopropylcarbodiimide. The molar amount of the condensing agent is 1.2 to 6 times the total molar amount of amino groups in the amino resin, preferably 2.5 to 3.5 times.

[0042] The coupling reaction requires the addition of an activating agent, which is selected from 1-hydroxybenzotriazole or N-hydroxy-7-azabenzotriazole, preferably 1-hydroxybenzotriazole. The amount of activating agent used is 1.2 to 6 times the total molar number of amino groups in the amino resin, preferably 2.5 to 3.5 times.

[0043] As a preferred embodiment of the present invention, the reagent for removing Fmoc protection is a PIP / DMF (piperidine / N,N-dimethylformamide) mixed solution, wherein the mixed solution contains 10-30% (V) piperidine. The amount of the Fmoc removal reagent is 5-15 mL per gram of amino resin, preferably 8-12 mL per gram of amino resin.

[0044] Preferably, the peptide resin is acid-hydrolyzed to remove both the resin and the side-chain protecting groups, yielding the crude product:

[0045] More preferably, the acid hydrolysate used during the acid hydrolysis of the peptide resin is a mixed solvent of trifluoroacetic acid (TFA), 1,2-ethylenedithiol (EDT) and water, with the volume ratio of the mixed solvent being: TFA 80-95%, EDT 1-10%, and the remainder being water.

[0046] More preferably, the volume ratio of the mixed solvent is: TFA 89-91%, EDT 4-6%, and the balance is water. Most preferably, the volume ratio of the mixed solvent is: TFA 90%, EDT 5%, and the balance is water.

[0047] The amount of acid hydrolysant used is 4 to 15 mL per gram of peptide resin; preferably, 7 to 10 mL per gram of peptide resin.

[0048] The pyrolysis time using the acid hydrolysate is 1 to 6 hours at room temperature, preferably 3 to 4 hours.

[0049] Furthermore, the crude product was purified by high performance liquid chromatography and lyophilized to obtain the pure product.

[0050] 1. Synthesis of peptide resins

[0051] Using Rink Amide BHHA resin as the carrier resin, peptide resins were prepared by sequentially coupling the peptides with the corresponding protected amino acids through de-Fmoc protection and coupling reactions.

[0052] (1) Access the first protected amino acid in the main chain

[0053] Take 0.03 mol of the first protected amino acid and 0.03 mol of HOBt, and dissolve them in an appropriate amount of DMF; take another 0.03 mol of DIC, and slowly add it to the DMF solution of the protected amino acid while stirring. Stir and react at room temperature for 30 minutes to obtain the activated protected amino acid solution for later use.

[0054] Take 0.01 mol of Rink amide MBHA resin (substitution value approximately 0.4 mmol / g), protect it with 20% PIP / DMF solution for 25 minutes, wash and filter to obtain Fmoc-free resin.

[0055] The activated solution of the first protected amino acid was added to the resin that had been de-Fmoc-treated, and the coupling reaction was carried out for 60–300 minutes. After filtration and washing, a resin containing one protected amino acid was obtained.

[0056] (2) Incorporation of main chain protected amino acids

[0057] Using the same method as described above for inserting the first protected amino acid into the main chain, the corresponding protected amino acids of the respective polypeptide sequences are sequentially inserted to obtain a resin containing main chain amino acids.

[0058] The protecting amino acid corresponding to the first Tyr is Boc-Tyr(tBu).

[0059] The protecting amino acid corresponding to Lys at position 16 is Fmoc-Lys(Alloc).

[0060] The protecting amino acid corresponding to the 20th Lys is Fmoc-Lys(Mtt).

[0061] (3) Introducing compound 1

[0062]

[0063] Take 0.03 mol of compound 1 and 0.03 mol of HOBt, and dissolve them in an appropriate amount of DMF; take another 0.03 mol of DIC, and slowly add it to the DMF solution of the protected amino acid while stirring. Stir and react at room temperature for 30 minutes to obtain the activated protected amino acid solution.

[0064] Remove the Mtt protecting group of the 20th Lys side chain using a 50% hexafluoroisopropanol / dichloromethane solution, 30 minutes each time, for a total of 5 times. Filter and wash to obtain the Mtt-free resin for later use.

[0065] The activated compound 1 solution was added to the resin after Mtt removal, and the coupling reaction was carried out for 60-300 minutes. After filtration and washing, a resin containing the first protected amino acid in the side chain was obtained.

[0066] (4) Cycloning

[0067] Take 5 mmol of tetraphenylphosphine palladium and 50 mmol of benzyl silane, dissolve them in an appropriate amount of dichloromethane, remove Alloc and All protecting groups for 8 hours, filter and wash to obtain Alloc and All-free resin for later use.

[0068] Take 0.03 mol HOBt and dissolve it in an appropriate amount of DMF; take another 0.03 mol DIC and dissolve it in an appropriate amount of DMF; add it to the alloc-free resin under stirring, and perform the coupling reaction for 60-300 minutes. Filter and wash to obtain the cyclized resin.

[0069] (5) Add side-chain protected amino acids or monoprotected fatty acids

[0070] Take the above cyclized resin, use 20% PIP / DMF solution to remove the Fmoc protection of compound 1 for 25 minutes, wash and filter to obtain the Fmoc-free resin.

[0071] Using the same method as described above for adding the first protected amino acid to the main chain, the corresponding protected amino acids and monoprotected fatty acids of the side chains are sequentially added to obtain peptide resin.

[0072] 2. Preparation of crude product

[0073] Take the above peptide resin and add a lysis reagent with a volume ratio of TFA:water:EDT = 95:5:5 (10 mL of lysis reagent per gram of resin). Stir well and react at room temperature for 3 hours. Filter the reaction mixture using a sintered glass funnel, collect the filtrate, wash the resin three times with a small amount of TFA, combine the filtrates and concentrate under reduced pressure. Add anhydrous diethyl ether to precipitate the precipitate, wash the precipitate three times with anhydrous diethyl ether, and dry under vacuum to obtain an off-white powder, which is the crude product.

[0074] 3. Preparation of pure products

[0075] Take the above crude product, add water and stir, adjust the pH to 8.0 with ammonia until completely dissolved, filter the solution through a 0.45μm mixed microporous membrane, and purify for later use;

[0076] Purification was performed using high performance liquid chromatography (HPLC). The chromatographic packing material was a 10 μm reversed-phase C18 column, and the mobile phase system was 0.1% TFA / water solution-0.1% TFA / acetonitrile solution. The chromatographic column was 30 mm * 250 mm, and the flow rate was 20 mL / min. Gradient elution was used, and the sample was injected repeatedly for purification. The crude product solution was loaded into the chromatographic column, and the mobile phase was started for elution. The main peak was collected, and after acetonitrile was removed, the purified intermediate concentrate was obtained.

[0077] The purified intermediate concentrate was filtered through a 0.45 μm filter membrane and set aside. High-performance liquid chromatography (HPLC) was used for salt exchange. The mobile phase system was 1% acetic acid / water solution-acetonitrile. The chromatographic packing material was a 10 μm reversed-phase C18 column (30 mm * 250 mm) with a flow rate of 20 mL / min (the flow rate can be adjusted according to different column specifications). Gradient elution and cyclic loading were used. The sample was loaded into the column, the mobile phase was started for elution, the chromatogram was collected, and the absorbance change was observed. The salt-exchanged main peak was collected and its purity was determined by analytical liquid chromatography. The salt-exchanged main peak solutions were combined, concentrated under reduced pressure to obtain pure acetic acid aqueous solution, and then freeze-dried to obtain pure peptide.

[0078] The following compounds were synthesized using the method described above:

[0079]

[0080] Example 2: Determination of GLP-1 activity

[0081] 1. Measurement Method

[0082] GLP-1R, upon stimulation by its specific agonist, activates the intracellular adenylate cyclase pathway, increases cAMP levels, and ultimately leads to insulin production and release. Cell lines stably transfected with GLP-1R were stimulated with the analyte, resulting in a rapid increase in intracellular cAMP levels. The relative light units (RLU) after each dose of stimulation were measured using a chemiluminescence method, and the EC50 of the agonist was calculated. This activity assay is currently a widely used method for detecting GLP-1 receptor agonist activity both domestically and internationally.

[0083] Using the CHO-K1 cell line stably expressing GLP-1R, the cells were stimulated with different concentrations of agonists. The EC50 of the agonists was calculated by measuring the relative light units after stimulation with each dose. 50 value.

[0084] 2. Measurement Results

[0085] The measurement results are shown in the table below:

[0086] compound <![CDATA[GLP-1 activity [EC 50 (pmol)]]> Tirzepatide 145.6 AOD243903 47.1 AOD243904 51.6 AOD243905 55.3 AOD243906 50.3

[0087] Example 3: Determination of GIP Activity

[0088] 1. Measurement Method

[0089] GIPR, when stimulated by its specific agonist, activates the intracellular adenylate cyclase pathway, increases cAMP levels, and ultimately leads to insulin production and release. Cell lines stably transfected with GIPR were stimulated with the analyte, resulting in a rapid increase in intracellular cAMP levels. The relative light units (RLU) after each dose of stimulation were measured using a chemiluminescence method, and the EC50 of the agonist was calculated. This activity assay is currently a widely used method for detecting GIP receptor agonist activity both domestically and internationally.

[0090] Using the CHO-K1 cell line stably expressing GIPR, the cells were stimulated with different concentrations of agonists. The EC50 of the agonists was calculated by measuring the relative light units after stimulation with each dose. 50 value.

[0091] 2. Measurement Results

[0092] The measurement results are shown in the table below:

[0093] compound <![CDATA[GIP activity [EC 50 (pmol)]]> Tirzepatide 42.6 AOD243903 30.9 AOD243904 24.0 AOD243905 28.4 AOD243906 29.7

Claims

1. A GIP-GLP-1 dual agonist compound or a pharmaceutically acceptable salt thereof with the following structural formula: 、 、 、 。 2. A pharmaceutical composition comprising the GIP-GLP-1 dual agonist compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. The use of the GIP-GLP-1 dual agonist compound of claim 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 2, in the preparation of a medicament for treating type II diabetes.

Citation Information

Patent Citations

  • GIP-GLP-1 dual agonist compounds and methods

    WO2013164483A1

  • Peptide compound

    WO2014192284A1

  • GIP / GLP-1 analogue

    CN111320683A

  • GLP-1R / GCGR / GIPR triple receptor agonist and application thereof

    CN114437181A